Researcher
Frank Claessens
- Disciplines:Endocrinology, Structural biology, Molecular and cell biology not elsewhere classified, Cancer biology, Urology and nephrology not elsewhere classified
Affiliations
- Laboratory of Molecular Endocrinology (Division)
Responsible
From1 Jan 2012 → Today - Laboratory of Molecular Endocrinology (Division)
Member
From1 Oct 2007 → Today - Faculty of Medicine (Faculty)
Member
From1 Oct 2000 → 31 Dec 2002
Projects
11 - 20 of 36
- The kidney as a non-classical target organ for androgen actionFrom1 Jan 2018 → 31 Dec 2021Funding: FWO research project (including WEAVE projects)
- Molecular biology of the dimerization functions of the androgen receptorFrom1 Jan 2018 → 31 Dec 2021Funding: FWO research project (including WEAVE projects)
- What is the role of recepter dimerization in androgen action?From5 Sep 2017 → 19 May 2022Funding: FWO fellowships
- Development of artificial nuclear receptors, the synthetic yeast approachFrom5 Sep 2017 → 14 Sep 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Clinical and preclinical studies of modulators of high-risk prostate cancer with metastatic potentialFrom1 Aug 2016 → 29 Apr 2022Funding: BOF - doctoral mandates, Private funding of national origin - undefined
- Role of hydroxymethylation as an epigenetic mark in prostate cancer biologyFrom1 Jan 2016 → 31 Dec 2019Funding: FWO research project (including WEAVE projects)
- Molecular biology of the steroid receptorsFrom1 Jan 2016 → 31 Dec 2022Funding: FWO scientific research network
- The role of androgens in calcium & phosphate homeostasis: focus on the bone-kidney axis in malesFrom5 Oct 2015 → 28 Sep 2020Funding: Own budget, for example: patrimony, inscription fees, gifts
- Structural optimization of MEL-6 and development towards a prostate cancer therapeuticFrom1 Oct 2015 → 30 Sep 2017Funding: IOF - Industrial Research Fund
- Nuclear-cytoplasmic transport as novel therapeutic target.From1 Oct 2014 → 30 Sep 2018Funding: IOF - Industrial Research Fund
Publications
1 - 10 of 223
- Discovery of a novel androgen receptor antagonist, MEL-6, with stereoselective activity and optimization of its metabolic stability.(2024)
Authors: Christine Helsen, Steven Joniau, Frank Claessens
Pages: 106476 - Re: Abiraterone and Olaparib for Metastatic Castration-resistant Prostate Cancer.(2024)
Authors: Alexander Giesen, Frank Claessens, Steven Joniau
Pages: 396 - Rational evolution for altering the ligand preference of estrogen receptor alpha(2024)
Authors: Xiao Yin Lee, Karin Voordeckers, Els Henckaerts, Vitor Bernardes Pinheiro, Frank Claessens, Kevin Verstrepen, Arnout Voet, Christine Helsen
- New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor Symposium(2024)
Authors: Frank Claessens
- Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants(2023)
Authors: Gert De Meerleer, Frank Claessens, Steven Joniau
Pages: 2065 - + - Global variation in diabetes diagnosis and prevalence based on fasting glucose and hemoglobin A1c(2023)
Authors: Frank Claessens, Dirk Vanderschueren
- Changes in bone and mineral homeostasis after short-term androgen deprivation therapy with or without androgen receptor signalling inhibitor - substudy of a single-centre, double blind, randomised, placebo-controlled phase 2 trial(2023)
Authors: Karel David, Nick Narinx, Leen Antonio, Dirk Vanderschueren, Frank Claessens, Steven Joniau, Brigitte Decallonne
- A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer.(2023)
Authors: Frank Claessens
Pages: 1166 - 1181 - Testosterone Restores Body Composition, Bone Mass, and Bone Strength Following Early Puberty Suppression in a Mouse Model Mimicking the Clinical Strategy in Trans Boys(2023)
Authors: Stefanie Doms, Sarah El Kharraz, Vera Maria Johanna Sommers, Karel David, Christa Maes, Leen Antonio, Brigitte Decallonne, Geert Carmeliet, Frank Claessens, Dirk Vanderschueren
Pages: 1497 - 1508 - Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients(2023)
Authors: Alexander Giesen, Loic Baekelandt, Herlinde Dumez, Wouter Everaerts, Frank Claessens, Steven Joniau